TG Therapeutics, Inc. (TGTX)
56.05
+1.78
(+3.28%)
USD |
NASDAQ |
Aug 24, 16:00
56.45
+0.40
(+0.71%)
After-Hours: 20:00
TG Therapeutics Enterprise Value : 8.510B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 8.510B |
| August 20, 2026 | 7.942B |
| August 19, 2026 | 8.115B |
| August 18, 2026 | 7.896B |
| August 17, 2026 | 7.746B |
| August 14, 2026 | 7.663B |
| August 13, 2026 | 7.541B |
| August 12, 2026 | 7.780B |
| August 11, 2026 | 7.841B |
| August 10, 2026 | 7.727B |
| August 07, 2026 | 7.819B |
| August 06, 2026 | 7.787B |
| August 05, 2026 | 7.838B |
| August 04, 2026 | 7.662B |
| August 03, 2026 | 7.270B |
| July 31, 2026 | 8.167B |
| July 30, 2026 | 8.396B |
| July 29, 2026 | 8.389B |
| July 28, 2026 | 8.602B |
| July 27, 2026 | 8.736B |
| July 24, 2026 | 8.781B |
| July 23, 2026 | 8.698B |
| July 22, 2026 | 8.266B |
| July 21, 2026 | 8.461B |
| July 20, 2026 | 8.462B |
| Date | Value |
|---|---|
| July 17, 2026 | 8.602B |
| July 16, 2026 | 8.611B |
| July 15, 2026 | 8.837B |
| July 14, 2026 | 8.605B |
| July 13, 2026 | 8.623B |
| July 10, 2026 | 8.946B |
| July 09, 2026 | 9.243B |
| July 08, 2026 | 8.963B |
| July 07, 2026 | 9.090B |
| July 06, 2026 | 8.693B |
| July 02, 2026 | 8.363B |
| July 01, 2026 | 8.395B |
| June 30, 2026 | 8.612B |
| June 29, 2026 | 8.770B |
| June 26, 2026 | 8.786B |
| June 25, 2026 | 8.450B |
| June 24, 2026 | 8.445B |
| June 23, 2026 | 8.497B |
| June 22, 2026 | 8.567B |
| June 18, 2026 | 8.387B |
| June 17, 2026 | 8.123B |
| June 16, 2026 | 7.976B |
| June 15, 2026 | 7.940B |
| June 12, 2026 | 7.820B |
| June 11, 2026 | 7.595B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Krystal Biotech, Inc. | 9.421B |
| MAIA Biotechnology, Inc. | 56.94M |
| Vericel Corp. | 2.116B |
| Incyte Corp. | 21.19B |
| Regeneron Pharmaceuticals, Inc. | 80.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 7.781M |
| Revenue (Quarterly) | 240.34M |
| Total Expenses (Quarterly) | 232.55M |
| EPS Diluted (Quarterly) | 0.0495 |
| Gross Profit Margin (Quarterly) | 82.86% |
| Profit Margin (Quarterly) | 3.24% |
| Earnings Yield | 4.90% |
| Operating Earnings Yield | 1.53% |
| Normalized Earnings Yield | 4.992 |